Nanopatent, licensing and ADIF rapid response technology question (Accurate Drug In Field TM):
You seem to have a good handle on NNVC IP rights and patents, so maybe you or someone else here can answer this.
Recently, re-reading some of the 10K and 10Q filings, I have noticed that while ADIF is listed prominently as an NNVC technology, there doesn't seem to be any discussion of licensing.
First, while various specific virus technologies are discussed as being licensed by NNVC from Theracour, I have not seen anything about a specific NNVC license or patents on the ADIF technology.
Since ADIF is and has been so prominently indicated in the filings, I would think NNVC would have everything lined up as to ownership or licensing. If so, great, but I would like to see the patent or license references if that is the case.
But second and more importantly, how are the rights and profits to be distributed between NNVC and Theracour if ADIF is used on a virus that is not licensed (yet, presumably?) to NNVC?
If NNVC has clear rights to ADIF, will they still have to negotiate with Theracour for the rights to design and manufacture the new drug - base micelle, ligands, combination?
Could this possibly delay the chance for rapid implementation of the rapid design capabilities of ADIF?
I may be wrong, but this looks to be another COI area that seems to need shoring up AFAIAC to spell out and protect NNVC shareholders (me).
News 
Market Data 
Discover 
